US4849407A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biologically active mosaic proteins
Assignee: Zymogenetics Inc
•
Filing: 1986-12-15
•
Granted: 1989-07-18
•
Expires: 2006-12-15
Abstract
Abstract Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the proteins may have two polypeptide chains, one of the chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of the chains being substantially homologous to either the A-chain or the B-chain of PDGF, the proteins being chemotactic or mitogenic for fibroblasts. Alternatively, each of the two polypeptide chains may be a mosaic of amino acid sequences as described above. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.
Inventors
- 👤 Mark J. Murray
- 👤 James D. Kelly
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 20:06
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; C07K14/435; C07K14/475; C07K14/49; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/62; C12N15/625; C12N15/63; C12N15/79; C12N15/80; C12N15/81; A; A61; A61K; A61K38/00; C07K2319/00; C07K2319/01; C07K2319/02; C07K2319/036; C07K2319/70; C07K2319/74; C07K2319/75; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/11011; C12N2740/11022; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/12; Y10S930/22; Y10S930/221
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
223 words
A protein having two polypeptide chains, one of said chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of said chains being substantially homologous to the A-chain of PDFG, said protein being chemotactic or mitogenic for fibroblasts, wherein said mosaic chain comprises a sequence selected from the group consisting of: (a) A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-109; and (b) A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-97 fused in reading frame to A-chain amino acids 92-104; and wherein said second chain comprises a sequence selected from the group consisting of: (a) the amino acid sequence of the A-chain of PDGF from amino acid 15 to amino acid 104; (b) the amino acid sequence of the A-chain of PDGF from amino acid 23 to amino acid 104; (c) the amino acid sequence of the A-chain of PDGF from amino acid 9 to amino acid 95; (d) the amino acid sequence of the A-chain of PDGF from amino acid 23 to amino acid 95; (e) the amino acid sequence of the A-chain of PDGF from amino acid 1 to amino acid 95; and (f) the amino acid sequence of the A-chain of PDGF from amino acid 1 to amino acid 104.
Claim 2
Dependent Claim
223 words
A protein having two polypeptide chains, one of said chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of said chains being substantially homologous to the A-chain of PDFG, said protein being chemotactic or mitogenic for fibroblasts, wherein said mosaic chain comprises a sequence selected from the group consisting of: (a) A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-109; and (b) A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-97 fused in reading frame to A-chain amino acids 92-104; and wherein said second chain comprises a sequence selected from the group consisting of: (a) the amino acid sequence of the A-chain of PDGF from amino acid 15 to amino acid 104; (b) the amino acid sequence of the A-chain of PDGF from amino acid 23 to amino acid 104; (c) the amino acid sequence of the A-chain of PDGF from amino acid 9 to amino acid 95; (d) the amino acid sequence of the A-chain of PDGF from amino acid 23 to amino acid 95; (e) the amino acid sequence of the A-chain of PDGF from amino acid 1 to amino acid 95; and (f) the amino acid sequence of the A-chain of PDGF from amino acid 1 to amino acid 104.
Claim 3
Dependent Claim
223 words
A protein having two polypeptide chains, one of said chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of said chains being substantially homologous to the B-chain of PDGF, said protein being chemotactic or mitogenic for fibroblasts, wherein said mosaic chain comprises a sequence selected from the group consisting of: (a) A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-109; and (b) A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-97 fused in reading frame to A-chain amino acids 92-104; and wherein said second chain comprises a sequence selected from the group consisting of: (a) the amino acid sequence of the B-chain of PDGF from amino acid 15 to amino acid 109; (b) the amino acid sequence of the B-chain of PDGF from amino acid 29 to amino acid 109; (c) the amino acid sequence of the B-chain of PDGF from amino acid 15 to amino acid 101; (d) the amino acid sequence of the B-chain of PDGF from amino acid 29 to amino acid 101; (e) the amino acid sequence of the B-chain of PDGF from amino acid 1 to amino acid 101; and (f) the amino acid sequence of the B-chain of PDGF from amino acid 1 to amino acid 109.
Claim 4
Dependent Claim
223 words
A protein having two polypeptide chains, one of said chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of said chains being substantially homologous to the B-chain of PDGF, said protein being chemotactic or mitogenic for fibroblasts, wherein said mosaic chain comprises a sequence selected from the group consisting of: (a) A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-109; and (b) A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-97 fused in reading frame to A-chain amino acids 92-104; and wherein said second chain comprises a sequence selected from the group consisting of: (a) the amino acid sequence of the B-chain of PDGF from amino acid 15 to amino acid 109; (b) the amino acid sequence of the B-chain of PDGF from amino acid 29 to amino acid 109; (c) the amino acid sequence of the B-chain of PDGF from amino acid 15 to amino acid 101; (d) the amino acid sequence of the B-chain of PDGF from amino acid 29 to amino acid 101; (e) the amino acid sequence of the B-chain of PDGF from amino acid 1 to amino acid 101; and (f) the amino acid sequence of the B-chain of PDGF from amino acid 1 to amino acid 109.
Claim 5
Dependent Claim
61 words
A protein having two polypeptide chains, each of said chains being a mosaic of amino acid sequences selected from the group consisting of: (a) A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-109; and (b) A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-97 fused in reading frame to A-chain amino acids 92-194.
Claim 6
Dependent Claim
61 words
A protein having two polypeptide chains, each of said chains being a mosaic of amino acid sequences selected from the group consisting of: (a) A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-109; and (b) A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-97 fused in reading frame to A-chain amino acids 92-194.
Claim 7
Dependent Claim
19 words
A wound-healing composition comprising a protein according to claim 1, in combination with a physiologically acceptable carrier or diluent.
Claim 8
Dependent Claim
19 words
A wound-healing composition comprising a protein according to claim 2, in combination with a physiologically acceptable carrier or diluent.
Claim 9
Dependent Claim
19 words
A wound-healing composition comprising a protein according to claim 3, in combination with a physiologically acceptable carrier or diluent.
Claim 10
Dependent Claim
26 words
The wound-healing composition of claim 4, 5 or 6 wherein the carrier or diluent is selected from the group consisting of albumin, saline and sterile water.
Claim 11
Dependent Claim
12 words
The wound-healing composition of claim 4, 5 or 6, including an adjuvant.
Claim 12
Dependent Claim
24 words
The wound-healing composition of claim 8 wherein the adjuvant is selected from the group consisting of collagen, hyaluronic acid preparations, fibronectin and factor XIII.
Claim 13
Dependent Claim
30 words
A method for enhancing the wound-healing process in warm-blooded animals, comprising administering to a warm-blooded animal an effective amount of a wound-healing composition according to claim 4, 5 or 6.
References Cited (Backward Citations)
US4350687A
Cited
GB2146335A
Cited
US4605413A
Cited
US4590003A
Cited
US4645828A
Cited
WO1985004413A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-17 | 1993-01-16 | 1993-07-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-17 | 1997-01-16 | 1997-07-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-17 | 2001-01-16 | 2001-07-18 | $7700.00 | Window Closed / Lapsed |